Versant Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $65K | Buy |
517
+108
| +26% | +$13.6K | 0.01% | 849 |
|
|
2025
Q1 | $45.2K | Buy |
409
+328
| +405% | +$36.3K | 0.01% | 908 |
|
|
2024
Q4 | $11.1K | Buy |
81
+39
| +93% | +$5.32K | ﹤0.01% | 1344 |
|
|
2024
Q3 | $4.84K | Sell |
42
-14
| -25% | -$1.61K | ﹤0.01% | 1306 |
|
|
2024
Q2 | $7.71K | Buy |
56
+49
| +700% | +$6.75K | ﹤0.01% | 1079 |
|
|
2024
Q1 | $965 | Hold |
7
| – | – | ﹤0.01% | 1552 |
|
|
2023
Q4 | $922 | Buy |
7
+3
| +75% | +$395 | ﹤0.01% | 1536 |
|
|
2023
Q3 | $450 | Sell |
4
-5
| -56% | -$563 | ﹤0.01% | 1712 |
|
|
2023
Q2 | $849 | Buy |
9
+5
| +125% | +$472 | ﹤0.01% | 1660 |
|
|
2023
Q1 | $397 | Sell |
4
-7
| -64% | -$695 | ﹤0.01% | 1621 |
|
|
2022
Q4 | $1.31K | Hold |
11
| – | – | ﹤0.01% | 1243 |
|
|
2022
Q3 | $1K | Hold |
11
| – | – | ﹤0.01% | 1296 |
|
|
2022
Q2 | $1K | Hold |
11
| – | – | ﹤0.01% | 1317 |
|
|
2022
Q1 | $1K | Buy |
+11
| New | +$1K | ﹤0.01% | 1330 |
|
|
2021
Q3 | – | Sell |
-3
| Closed | – | – | 1541 |
|
|
2021
Q2 | $0 | Buy |
+3
| New | – | ﹤0.01% | 1544 |
|